Get started
Author

Cori Ann Sherwin

Observed names: C. Sherwin, Cori Ann J. Sherwin, Cori-Ann Sherwin
ORCID: 0009-0008-8818-4567
Observed ORCID: 0009-0008-8818-4567
OpenAlex ID: A5024845646
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
2019 · Richard D. Kim, Debashis Sarker, et al. · Cancer Discovery · 264
PDF
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2023 · Vivek Subbiah, Vaibhav Sahai, et al. · Cancer Discovery · 127
PDF
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
2019 · Megan A. Hatlen, Oleg Schmidt-Kittler, et al. · Cancer Discovery · 112
First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.
2021 · Alison M. Schram, Suneel Deepak Kamath, et al. · Journal of Clinical Oncology · 13
Abstract P02-02: First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors
2021 · Lipika Goyal, Mitesh Borad, et al. · Molecular Cancer Therapeutics · 12
Data from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2023 · Vivek Subbiah, Vaibhav Sahai, et al. · 1
Development of the Fibrodysplasia Ossificans Progressiva FLare EXperience Revised (FOP-FLEX-R©) Questionnaire: A Patient-Reported Outcome Measure
2026 · Robert J. Pignolo, Edward C. Hsiao, et al. · Bone
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
2025 · Vivek Subbiah, Vaibhav Sahai, et al.
PDF
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Table S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024 · Vivek Subbiah, Vaibhav Sahai, et al.
Works count: 116
Citation count: 529
H-index: 5
I10-index: 5
Year
Topic
Type